阿尔凯默斯 ALKS 深 沪
等待开盘 08-10 09:30:00 美东时间
49.17
+0.800
+1.65%
华盛通- 最 高50.85
- 今 开49.05
- 成交量 95.69万股
- 最 低 48.21
- 昨 收 48.37
- 总市值 806.39万
- 52周最高 55.67
- 市盈率 静 --
- 换手率 583.46%
- 52周最低 25.165
- 委 比 -91.16%
- 总股本 0.00亿
- 历史最高 80.71
- 量 比 0.61
- 振 幅 5.46%
- 历史最低 1.10
- 每 手 1
- 风险率 7.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study
Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom improvements in NT1 and NT2 narcolepsy.
07-13 23:06
Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties
On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal") terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025
07-08 20:10
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
Alkermes shares climbed after phase 3 LUMRYZ data met key endpoints in idiopathic hypersomnia as analysts raised price targets.
05-13 02:27
Alkermes Appoints Blair Jackson As CEO Succeeding Richard Pops, Effective August 1
— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes —— Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief
02-25 19:59
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal
Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.
2025-11-15 00:37
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
从产品出口到标准协同：新能源汽车出海的模式跃迁
原标题：从产品出口到标准协同：新能源汽车出海的模式跃迁 中国新能源汽车出口正从规模扩张转向质量跃升。核心突破在于国际标准认证体系的打通，动力电池通过欧盟EC...
2025-08-12 17:04
阿尔凯默斯盘中异动 股价大涨5.01%
北京时间2024年10月12日02时35分，阿尔凯默斯（ALKS.us）股票出现波动，股价急速拉升5.01%。截至发稿，该股报28.74美元/股，成交量79.2642万股，换手率0.48%，振幅5.26%。 最近的财报数据显示，该股实现营业收入3.99亿美元，净利润94.66百万美元，每股收益0.54美元，毛利3.36亿美元，市盈率16.79倍。 机构评级方面，在所有14家参与评级的机构中，57%的券商给予买入建议，36%的券商给予持有建议，7%的券商给予卖出建议。 阿尔凯默斯股票所在的制药行业中，整体涨幅为1.30%。其相关个股中，Cyclo Therapeutics Inc C/Wts 1...
2024-10-12 02:35
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Across the recent three months, 6 analysts have shared their insights on Alkerm...
2024-09-17 05:01
Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Alkermes (NASDAQ:ALKS) with a Overweight and maintains $48 price target.
2024-09-16 23:19
